Strand Life Sciences’ Post

Ewing’s sarcoma is an extremely rare malignancy with an incidence of one case per million and a prevalence of 200 cases in the United States. In this paper, the authors present an overview of the present and future therapeutic perspectives for relapsed and refractory Ewing’s #sarcoma, based on the molecular pathways active in this rare cancer. 📝 Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype — Caltavituro, et al. Full text is available 👇 https://lnkd.in/dZsk99pG #medicine #health #research #science 

Genetics play a significant role in cancer risk. This module equips GPs with the tools to identify patients at risk of familial breast or colorectal cancer and make appropriate referrals. https://bit.ly/3Tnq6xR #cpd #cme #meded #gp

🌟 Day 2 - Session 7: Innovative Approaches in Cancer Research, From Microbiome to Omics 🌟 🗣️Chaired by: Prof. Shekhar Mande, Savitribai Phule Pune University 🎤Talk by: Dr. Nagarajan (Raj) Kannan, PhD Molecular Medicine, Mayo Clinic, USA on "Gut Microbiome and Metastatic Breast Cancer Control: A New Frontier". #ICGA2024 #CancerResearch #AIlinHealthcare #OncoGenomics #Omics #Genomics #HealthcareInnovation #PrecisionMedicine #NetworkingOpportunity #LifeSciences #CancerBreakthroughs #Oncology

“The researchers then performed extensive genomic profiling using advanced sequencing techniques, allowing them to identify recurrent genomic features and mutations associated with the disease. The result was the individualized risk model in multiple myeloma or IRMMa. The predictive model uses advanced statistical methodologies such as deep neural networks to generate individualized overall survival and event-free survival predictions for multiple myeloma patients. Rigorous validation of the IRMMa model using independent datasets was performed to ensure its accuracy and reliability in diverse patient populations. Additionally, the researchers analyzed treatment outcomes and variance among different therapeutic regimens, aiming to identify optimal treatment approaches tailored to individual patient characteristics. “- for such an awful cancer that impact the elderly as well as some below the age 50, its great to see work done to tailor treatment for the disease especially as this cancer can be chemo and radiotherapy resistant! #targetedtherapy #cancerresearch #multiplemyeloma #bloodcancer #interesting

#HTAN researchers @ Stanford University School of Medicine are generating a #PreCancer atlas of #ColorectalCancer/ #CRC to inform #diagnostic, #preventative, & #therapeutic strategies. Focused on the #RareDisease #familialadenomatouspolyposis/ #FAP #colorectalcancer syndrome as a model to develop #precisiontherapy, #ctDNA screening, #precisionprevention of sporadic #CRC, Invitae privileged to collaborate Pubs: "Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer" https://lnkd.in/gHfEdTqR Nature Source Genetics "The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution" https://lnkd.in/g97tG6DV Cell Press Michael Snyder #DrJimFord Christina Curtis William Greenleaf ANSHUL KUNDAJE et al. https://lnkd.in/gG8P-_zb #CancerMoonshot Snyderlab Stanford Stanford Snyder Lab Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) #ColorectalCancerAwarenessMonth #HereditaryGICancer National Cancer Institute (NCI)

Welcome to American Cancer Society, Dr Pia Banerjee, PhD. As the inaugural Director of Cancer Innovation & Transformation, Pia will lead our strategy related to addressing patient needs in the post-diagnosis setting. Seismic shifts in how care is delivered (e.g., formulation changes), where is it delivered (e.g., site of service change), how it is monitored (e.g., remote patient monitoring, PRO’s), and how innovations are accessed (e.g., MCED, polygenic risk scores, NGS testing), require us to shift our programs (or create new ones) to help us better meet people where they are. Reporting into Shanthi Sivendran MD, MSCR, MBA, Dr Banerjee joins Bonny Morris, PhD, MSPH, RN and Anu Agrawal as a dynamic leadership team in our Cancer Treatment Support vertical of Patient Support. The future is bright. https://lnkd.in/esZw2yBS

Imagine a world where every cancer patient receives a treatment plan tailored specifically to their unique genetic makeup. Despite the complexity of cancer genetics, where each tumor harbors an average of four to five genetic driver alterations, this vision is becoming a reality 🎯 Discover how AI is revolutionizing precision oncology, enhancing treatment efficacy, and improving patient outcomes from our very own founder, CEO and CSO, Istvan Petak, MD, PhD. Watch the full Labroots webinar recording here: https://lnkd.in/dNEz4Uua #PrecisionOncology #AI #CancerTreatment #GenomateHealth #PersonalizedMedicine

Unlocking Precision Medicine: A New Era in Blood Cancer Care Precision medicine, built on understanding each patient's unique genetic and molecular profile, is revolutionizing blood cancer treatment. Through advanced genetic profiling, oncologists can tailor targeted therapies, improving outcomes and minimizing side effects. Challenges remain, but collaborative efforts among researchers, healthcare providers, and patients promise continued progress. Together, let's embrace precision medicine and its potential to transform the lives of those affected by blood cancers. Check out my blog here  #PrecisionMedicine #BloodCancerCare #PersonalizedTreatment

Heat shock protein 70 (Hsp70) is frequently overexpressed in many different tumor types. In this paper, the authors aimed to describe Hsp70-based selection system which appears superior to an EpCAM-37 based approach in the isolation of CTCs from patients with metastatic cancer. . 📝 Hsp70—A Universal Biomarker for Predicting Therapeutic Failure in Human Female Cancers and a Target for CTC Isolation in Advanced Cancers — Xanthopoulos, et al. Full text is available 👇 https://lnkd.in/d6nBcdZq #medicine #health #research #science